Phase 1b results of avelumab in patients (pts) with previously treated metastatic melanoma enrolled in the JAVELIN Solid Tumor trial, including updated subgroup analyses.

Ulrich Keilholz,Janice M. Mehnert,Sebastian Bauer,H. Bourgeois,Manish R. Patel,Donald Gravenor,John Nemunaitis,Matthew H. Taylor,Lucjan S. Wyrwicz,Keun-Wook Lee,Vijay Kasturi,Kevin M. Chin,Anja von Heydebreck,James L. Gulley

Phase 1b results of avelumab in patients (pts) with previously treated metastatic melanoma enrolled in the JAVELIN Solid Tumor trial, including updated subgroup analyses.

2018

Ulrich Keilholz
Janice M. Mehnert
Sebastian Bauer
H. Bourgeois
Manish R. Patel
Donald Gravenor
John Nemunaitis
Matthew H. Taylor
Lucjan S. Wyrwicz
Keun-Wook Lee
Vijay Kasturi
Kevin M. Chin
Anja von Heydebreck
James L. Gulley

e21531Background: Avelumab is a human anti–PD-L1 IgG1 monoclonal antibody approved for the treatment of metastatic Merkel cell carcinoma and advanced urothelial carcinoma progressed on platinum the...

Keywords:

Melanoma
Avelumab
Pathology
Cancer research
Javelin
Medicine
previously treated
metastatic melanoma
Merkel cell carcinoma
in patient
urothelial carcinoma
solid tumor
Oncology
Internal medicine
Monoclonal antibody

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations